GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (OTCPK:KRBP) » Definitions » Book Value per Share

Kiromic BioPharma (Kiromic BioPharma) Book Value per Share : $-5.60 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kiromic BioPharma Book Value per Share?

Kiromic BioPharma's book value per share for the quarter that ended in Mar. 2024 was $-5.60.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Kiromic BioPharma was 48.60% per year. The lowest was 48.60% per year. And the median was 48.60% per year.

Kiromic BioPharma's current price is $3.20. Its book value per share for the quarter that ended in Mar. 2024 was $-5.60. Hence, today's PB Ratio of Kiromic BioPharma is .

During the past 6 years, the highest P/B Ratio of Kiromic BioPharma was 15.28. The lowest was 0.00. And the median was 0.00.


Kiromic BioPharma Book Value per Share Historical Data

The historical data trend for Kiromic BioPharma's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiromic BioPharma Book Value per Share Chart

Kiromic BioPharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial -65.61 46.48 52.92 -8.91 -7.25

Kiromic BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.31 -5.35 -3.82 -7.25 -5.60

Competitive Comparison of Kiromic BioPharma's Book Value per Share

For the Biotechnology subindustry, Kiromic BioPharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiromic BioPharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiromic BioPharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Kiromic BioPharma's PB Ratio falls into.



Kiromic BioPharma Book Value per Share Calculation

Kiromic BioPharma's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-9.12-0.00)/1.26
=-7.25

Kiromic BioPharma's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-7.21-0.00)/1.29
=-5.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Kiromic BioPharma  (OTCPK:KRBP) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Kiromic BioPharma Book Value per Share Related Terms

Thank you for viewing the detailed overview of Kiromic BioPharma's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiromic BioPharma (Kiromic BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
7707 Fannin Street, Suite 140, Houston, TX, USA, 77054
Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.
Executives
Brian Hungerford officer: CFO 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Pamela Misajon director 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Michael Catlin director 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Karen Reeves director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Francis X Tirelli director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Daniel Grant Clark officer: Interim CFO 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Internati Maurizio Chiriva director, officer: Chairman, CEO, and President 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Michael Charles Ryan officer: Chief Technology Officer 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Ignacio Nunez officer: See Remarks 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Jerry A. Schneider director ONE VISION DRIVE, NATICK MA 01760
Michael Nagel director C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Pietro Bersani director C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017
Scott Dahlbeck officer: Chief Medical Officer 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Americo Cicchetti director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Gianluca Rotino director, officer: CSIO 7707 FANNIN, SUITE 140, HOUSTON TX 77054

Kiromic BioPharma (Kiromic BioPharma) Headlines

From GuruFocus

Kiromic BioPharma Arranges Up to $10 Million Financing

By Business Wire Business Wire 10-27-2022